What Sectors, Stages, and Regions Does ND Capital Invest In?
Updated
ND Capital invests across the life sciences, physical sciences, and data sciences, at multiple stages and technology types, in companies located in the United States and Europe. The firm describes itself as stage-agnostic and sector-agnostic within those broad scientific domains. Its stated focus is on "disruptive technologies" and on breakthroughs that emerge where scientific disciplines converge.
Sectors: life, physical, and data sciences
ND Capital (formerly NanoDimension) was founded in 2002 around the belief that major breakthroughs would come from the convergence of scientific fields. Its portfolio is organized into three groupings shown on the site: Physical Science, Life Science, and Data Science.
The practical implication for a founder or researcher is that the firm does not limit itself to a single vertical. A materials or energy technology, a therapeutics platform, and a data-driven tool can all fit the same thesis if the underlying science is differentiated. The firm's origin story reinforces this: its founder encountered nanotechnology while doing research between the physics and chemistry departments at EPFL and concluded that expertise would be needed "to differentiate science from science fiction."
Stages: no single-stage restriction
The site states plainly that ND Capital invests "across sectors, stages and technologies." It does not publish a stage-by-stage breakdown, fund-by-fund allocation, or check-size ranges, so you should not assume a specific entry point such as seed-only or growth-only. What the site does emphasize is how the firm works after investing: it describes itself as thinking "like company owners" and helping build "world-class, impactful, lasting companies," operating as one team to identify, evaluate, and support investments.
For a company evaluating fit, the useful signal is the science thesis and the convergence angle rather than a stage label. If your work sits at the intersection of disciplines and is defensible on scientific grounds, the stated criteria are more relevant than a funding-stage checklist.
Regions: US and Europe, with transatlantic support
ND Capital invests across the United States and Europe. It names teams in Silicon Valley, Switzerland, and the Cayman Islands, and says these teams help portfolio companies "bridge the Atlantic to attract capital, talent, and business partners."
This is the most concrete operational detail on the site, and it matters for European founders in particular. The firm's own history notes that after raising its first partnership, the founder concluded that despite strong science in Europe, the US offered better investment opportunities — and has commuted between Switzerland and Boston/Silicon Valley since 2007. A European deep-tech team should read the transatlantic bridge as a real part of the value proposition, not just marketing language.
Scale and track record signals
| Signal | Detail from the site |
|---|---|
| Founded | 2002 (as NanoDimension) |
| Assets under management | More than $800M across multiple funds |
| Geographic footprint | US and Europe; teams in Silicon Valley, Switzerland, Cayman Islands |
| Portfolio | Organized into Physical Science, Life Science, and Data Science, with a large alumni roster |
| Leadership | Aymeric Sallin, Founder & CEO; board roles at Crocus Technology, H55, Natron Energy, Tarveda Therapeutics, Selecta Biosciences |
The named board seats give a sense of the firm's range: semiconductor/magnetic technology (Crocus), electric aviation (H55), grid-scale energy storage (Natron), and therapeutics (Tarveda, Selecta). That spread is consistent with the cross-sector, cross-stage description.
How to judge whether you fit
Use the following as a practical screen, based only on what the firm states:
- Science-first differentiation. Can you articulate why your technology is a genuine breakthrough rather than an incremental improvement?
- Convergence. Does your work draw on more than one scientific discipline? This is the firm's core stated belief.
- Geography. Are you based in, or able to operate across, the US or Europe?
- Stage openness. Do not self-screen out on stage alone, since the firm says it invests across stages — but also do not assume a specific check size, as none is published.
What the site does not disclose: fund sizes per vintage, typical investment amounts, ownership targets, or a formal pitch process. Those details would need to come from direct contact; the team page lists individual email addresses in the firstname-initials format (for example, [email protected] for the founder).